VCYT
HealthcareVeracyte Inc
$41.19+8.22 (+24.93%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VCYT Today?
No stock-specific AI insight has been generated for VCYT yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$3.3B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume3.0M
Avg Volume (10D)—
Shares Outstanding79.8M
VCYT News
22 articles- Veracyte (VCYT) Is Up 23.8% After Raising 2026 Guidance And Expanding Decipher Cancer StudiesSimply Wall Street·May 9, 2026
- Veracyte (VCYT) general counsel sells 10,204 shares in 10b5-1 planStock Titan·May 8, 2026
- Why Veracyte Stock Is Skyrocketing Higher This WeekMotley Fool·May 8, 2026
- Veracyte, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextYahoo Finance·May 7, 2026
- Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for InvestorsYahoo Finance·May 7, 2026
- Veracyte Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Veracyte (VCYT) Beats Q1 Earnings and Revenue EstimatesYahoo Finance·May 6, 2026
- Veracyte, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Veracyte (VCYT) Q1 2026 Earnings TranscriptMotley Fool·May 5, 2026
- Veracyte Announces First Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a BetYahoo Finance·May 5, 2026
- Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 4, 2026
- A Look At Veracyte (VCYT) Valuation As New Decipher Bladder And Prostate Data Heads To AUA 2026Yahoo Finance·May 3, 2026
- Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic CancersYahoo Finance·Apr 28, 2026
- Veracyte (VCYT) Recently Broke Out Above the 50-Day Moving AverageYahoo Finance·Apr 27, 2026
- If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth NowYahoo Finance·Apr 27, 2026
- Jefferies Initiates Coverage of Caris Life Sciences Inc. (CAI) With a Buy RatingYahoo Finance·Apr 20, 2026
- Is Veracyte (VCYT) Offering Value After Mixed Returns And Conflicting Valuation SignalsYahoo Finance·Apr 19, 2026
- Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026Yahoo Finance·Apr 14, 2026
- Is Veracyte Stock the Right Pick for Your Portfolio Now?Yahoo Finance·Mar 31, 2026
- Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?Yahoo Finance·Mar 27, 2026
- Veracyte Names Kevin Haas as Chief Development and Technology OfficerYahoo Finance·Mar 16, 2026
All 22 articles loaded
Price Data
Open$39.00
Previous Close$32.97
Day High$41.66
Day Low$35.54
52 Week High—
52 Week Low—
Fundamentals
Market Cap$3.3B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume3.0M
Avg Volume (10D)—
Shares Outstanding79.8M
About Veracyte Inc
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
HealthcareSERVICES-MEDICAL LABORATORIES
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICSERVICES-MEDICAL LABORATORIES
CIK—
Composite FIGI—
Share Class FIGI—